SDGR
Schrödinger, Inc.
$27.29
-1.61
(-5.57%)
Mkt Cap
2.04B
Volume
4,555,596
52W Range
10.945-33.78
Sector
Technology
Beta
1.62
EPS (TTM)
-0.74 USD
P/E Ratio
-12.68
Revenue (TTM)
259.04M USD
Rev Growth (5Y)
+18.8%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$3.83
Overvalued
strong signal
612.4% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 255.87M | 207.54M | 216.67M | 180.96M | 137.93M | 108.09M | 85.54M | 66.64M | 55.69M |
| Net Income | (103.27M) | (187.12M) | 40.72M | (149.19M) | (100.39M) | (24.46M) | (24.57M) | (28.43M) | (17.39M) |
| EPS | -1.41 | -2.57 | 0.57 | -2.10 | -1.43 | -0.44 | -0.41 | -0.59 | -3.07 |
| Free Cash Flow | 12.46M | (164.68M) | (150.14M) | (127.70M) | (77.84M) | 14.22M | (27.89M) | (28.97M) | (19.01M) |
| FCF / Share | 0.17 | -2.27 | -2.09 | -1.79 | -1.10 | 0.24 | -0.44 | -0.60 | -3.35 |
| Operating CF | 13.90M | (157.37M) | (136.73M) | (119.68M) | (70.67M) | 16.76M | (26.06M) | (23.71M) | (15.31M) |
| Total Assets | 726.16M | 823.23M | 802.96M | 688.59M | 756.49M | 746.26M | 155.27M | 120.73M | 58.02M |
| Total Debt | 109.23M | 117.83M | 127.88M | 116.49M | 79.87M | 11.76M | 14.47M | 0 | 0 |
| Cash & Equiv | 230.52M | 147.33M | 155.31M | 90.47M | 120.27M | 202.30M | 25.99M | 77.72M | 9.96M |
| Book Value | 364.05M | 421.44M | 548.56M | 447.89M | 557.07M | 624.01M | (93.36M) | (71.56M) | (45.36M) |
| Return on Equity | -0.28 | -0.44 | 0.07 | -0.33 | -0.18 | -0.04 | N/A | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.89M | 58.59M | 87.23M | 54.32M | 54.76M | 59.55M | 88.32M | 35.29M | 47.33M | 36.60M | 74.13M | 42.57M |
| Net Income | 5.97M | (60.03M) | 32.51M | (32.80M) | (43.17M) | (59.81M) | (40.22M) | (38.14M) | (54.05M) | (54.72M) | (30.67M) | (62.02M) |
| EPS | 0.08 | -0.81 | 0.44 | -0.45 | -0.59 | -0.82 | -0.55 | -0.52 | -0.74 | -0.76 | -0.43 | -0.86 |
| Free Cash Flow | 63.38M | (17.34M) | (16.13M) | (62.36M) | (52.51M) | 143.47M | (31.99M) | (34.60M) | (54.72M) | (43.37M) | (39.73M) | (54.86M) |
| FCF / Share | 0.85 | -0.23 | -0.22 | -0.85 | -0.72 | 1.96 | -0.44 | -0.48 | -0.75 | -0.60 | -0.55 | -0.76 |
| Operating CF | 63.74M | (14.83M) | (16.09M) | (61.87M) | (52.20M) | 144.06M | (31.11M) | (33.26M) | (53.72M) | (39.28M) | (37.26M) | (49.94M) |
| Total Assets | 640.39M | 634.19M | 726.16M | 653.66M | 688.24M | 743.03M | 823.23M | 669.30M | 688.37M | 737.76M | 802.96M | 794.15M |
| Total Debt | 107.98M | 106.96M | 109.23M | 111.43M | 114.31M | 116.16M | 117.83M | 120.14M | 123.93M | 125.92M | 127.88M | 129.00M |
| Cash & Equiv | 287.85M | 260.25M | 230.52M | 181.87M | 219.90M | 326.00M | 147.33M | 160.42M | 108.11M | 130.24M | 161.07M | 249.38M |
| Book Value | 328.96M | 313.55M | 364.05M | 321.35M | 342.87M | 373.50M | 421.44M | 449.43M | 473.98M | 513.71M | 548.56M | 563.58M |
| Return on Equity | 0.02 | -0.19 | 0.09 | -0.10 | -0.13 | -0.16 | -0.10 | -0.08 | -0.11 | -0.11 | -0.06 | -0.11 |
SDGR News
Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains?
Schrödinger: Company Creation Is Now The Real Drug Business
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. (SDGR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Schrodinger (SDGR) Soars 12.1%: Is Further Upside Left in the Stock?
AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs
Jupiter Topco LLC Acquires Shares of 28,299 Schrodinger, Inc. $SDGR
Schrödinger to Present at Morgan Stanley Global Healthcare Conference
BlackRock Inc. Buys New Shares in Schrodinger, Inc. $SDGR